Copyright Reports & Markets. All rights reserved.

Global Aldult CAR T-cell Therapy Market 2026 by Company, Regions, Type and Application, Forecast to 2032

Request for Sample of this report
Buy now

1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Classification of Aldult CAR T-cell Therapy by Type
    • 1.3.1 Overview: Global Aldult CAR T-cell Therapy Market Size by Type: 2021 Versus 2025 Versus 2032
    • 1.3.2 Global Aldult CAR T-cell Therapy Consumption Value Market Share by Type in 2025
    • 1.3.3 CD19
    • 1.3.4 BCMA
    • 1.3.5 Others
  • 1.4 Global Aldult CAR T-cell Therapy Market by Application
    • 1.4.1 Overview: Global Aldult CAR T-cell Therapy Market Size by Application: 2021 Versus 2025 Versus 2032
    • 1.4.2 Multiple Myeloma
    • 1.4.3 B-Cell Lymphoma (BCL)
    • 1.4.4 Acute Lymphoblastic Leukemia (ALL)
    • 1.4.5 Others
  • 1.5 Global Aldult CAR T-cell Therapy Market Size & Forecast
  • 1.6 Global Aldult CAR T-cell Therapy Market Size and Forecast by Region
    • 1.6.1 Global Aldult CAR T-cell Therapy Market Size by Region: 2021 VS 2025 VS 2032
    • 1.6.2 Global Aldult CAR T-cell Therapy Market Size by Region, (2021-2032)
    • 1.6.3 North America Aldult CAR T-cell Therapy Market Size and Prospect (2021-2032)
    • 1.6.4 Europe Aldult CAR T-cell Therapy Market Size and Prospect (2021-2032)
    • 1.6.5 Asia-Pacific Aldult CAR T-cell Therapy Market Size and Prospect (2021-2032)
    • 1.6.6 South America Aldult CAR T-cell Therapy Market Size and Prospect (2021-2032)
    • 1.6.7 Middle East & Africa Aldult CAR T-cell Therapy Market Size and Prospect (2021-2032)

2 Company Profiles

  • 2.1 Bristol Myers Squibb，BMS
    • 2.1.1 Bristol Myers Squibb，BMS Details
    • 2.1.2 Bristol Myers Squibb，BMS Major Business
    • 2.1.3 Bristol Myers Squibb，BMS Aldult CAR T-cell Therapy Product and Solutions
    • 2.1.4 Bristol Myers Squibb，BMS Aldult CAR T-cell Therapy Revenue, Gross Margin and Market Share (2021-2026)
    • 2.1.5 Bristol Myers Squibb，BMS Recent Developments and Future Plans
  • 2.2 Johnson & Johnson
    • 2.2.1 Johnson & Johnson Details
    • 2.2.2 Johnson & Johnson Major Business
    • 2.2.3 Johnson & Johnson Aldult CAR T-cell Therapy Product and Solutions
    • 2.2.4 Johnson & Johnson Aldult CAR T-cell Therapy Revenue, Gross Margin and Market Share (2021-2026)
    • 2.2.5 Johnson & Johnson Recent Developments and Future Plans
  • 2.3 Gilead Sciences
    • 2.3.1 Gilead Sciences Details
    • 2.3.2 Gilead Sciences Major Business
    • 2.3.3 Gilead Sciences Aldult CAR T-cell Therapy Product and Solutions
    • 2.3.4 Gilead Sciences Aldult CAR T-cell Therapy Revenue, Gross Margin and Market Share (2021-2026)
    • 2.3.5 Gilead Sciences Recent Developments and Future Plans
  • 2.4 Novartis
    • 2.4.1 Novartis Details
    • 2.4.2 Novartis Major Business
    • 2.4.3 Novartis Aldult CAR T-cell Therapy Product and Solutions
    • 2.4.4 Novartis Aldult CAR T-cell Therapy Revenue, Gross Margin and Market Share (2021-2026)
    • 2.4.5 Novartis Recent Developments and Future Plans
  • 2.5 JW Therapeutics
    • 2.5.1 JW Therapeutics Details
    • 2.5.2 JW Therapeutics Major Business
    • 2.5.3 JW Therapeutics Aldult CAR T-cell Therapy Product and Solutions
    • 2.5.4 JW Therapeutics Aldult CAR T-cell Therapy Revenue, Gross Margin and Market Share (2021-2026)
    • 2.5.5 JW Therapeutics Recent Developments and Future Plans
  • 2.6 Imunopharm Technology Co., Ltd.
    • 2.6.1 Imunopharm Technology Co., Ltd. Details
    • 2.6.2 Imunopharm Technology Co., Ltd. Major Business
    • 2.6.3 Imunopharm Technology Co., Ltd. Aldult CAR T-cell Therapy Product and Solutions
    • 2.6.4 Imunopharm Technology Co., Ltd. Aldult CAR T-cell Therapy Revenue, Gross Margin and Market Share (2021-2026)
    • 2.6.5 Imunopharm Technology Co., Ltd. Recent Developments and Future Plans
  • 2.7 CARsgen Therapeutics
    • 2.7.1 CARsgen Therapeutics Details
    • 2.7.2 CARsgen Therapeutics Major Business
    • 2.7.3 CARsgen Therapeutics Aldult CAR T-cell Therapy Product and Solutions
    • 2.7.4 CARsgen Therapeutics Aldult CAR T-cell Therapy Revenue, Gross Margin and Market Share (2021-2026)
    • 2.7.5 CARsgen Therapeutics Recent Developments and Future Plans
  • 2.8 Cartesian Therapeutics
    • 2.8.1 Cartesian Therapeutics Details
    • 2.8.2 Cartesian Therapeutics Major Business
    • 2.8.3 Cartesian Therapeutics Aldult CAR T-cell Therapy Product and Solutions
    • 2.8.4 Cartesian Therapeutics Aldult CAR T-cell Therapy Revenue, Gross Margin and Market Share (2021-2026)
    • 2.8.5 Cartesian Therapeutics Recent Developments and Future Plans

3 Market Competition, by Players

  • 3.1 Global Aldult CAR T-cell Therapy Revenue and Share by Players (2021-2026)
  • 3.2 Market Share Analysis (2025)
    • 3.2.1 Market Share of Aldult CAR T-cell Therapy by Company Revenue
    • 3.2.2 Top 3 Aldult CAR T-cell Therapy Players Market Share in 2025
    • 3.2.3 Top 6 Aldult CAR T-cell Therapy Players Market Share in 2025
  • 3.3 Aldult CAR T-cell Therapy Market: Overall Company Footprint Analysis
    • 3.3.1 Aldult CAR T-cell Therapy Market: Region Footprint
    • 3.3.2 Aldult CAR T-cell Therapy Market: Company Product Type Footprint
    • 3.3.3 Aldult CAR T-cell Therapy Market: Company Product Application Footprint
  • 3.4 New Market Entrants and Barriers to Market Entry
  • 3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type

  • 4.1 Global Aldult CAR T-cell Therapy Consumption Value and Market Share by Type (2021-2026)
  • 4.2 Global Aldult CAR T-cell Therapy Market Forecast by Type (2027-2032)

5 Market Size Segment by Application

  • 5.1 Global Aldult CAR T-cell Therapy Consumption Value Market Share by Application (2021-2026)
  • 5.2 Global Aldult CAR T-cell Therapy Market Forecast by Application (2027-2032)

6 North America

  • 6.1 North America Aldult CAR T-cell Therapy Consumption Value by Type (2021-2032)
  • 6.2 North America Aldult CAR T-cell Therapy Market Size by Application (2021-2032)
  • 6.3 North America Aldult CAR T-cell Therapy Market Size by Country
    • 6.3.1 North America Aldult CAR T-cell Therapy Consumption Value by Country (2021-2032)
    • 6.3.2 United States Aldult CAR T-cell Therapy Market Size and Forecast (2021-2032)
    • 6.3.3 Canada Aldult CAR T-cell Therapy Market Size and Forecast (2021-2032)
    • 6.3.4 Mexico Aldult CAR T-cell Therapy Market Size and Forecast (2021-2032)

7 Europe

  • 7.1 Europe Aldult CAR T-cell Therapy Consumption Value by Type (2021-2032)
  • 7.2 Europe Aldult CAR T-cell Therapy Consumption Value by Application (2021-2032)
  • 7.3 Europe Aldult CAR T-cell Therapy Market Size by Country
    • 7.3.1 Europe Aldult CAR T-cell Therapy Consumption Value by Country (2021-2032)
    • 7.3.2 Germany Aldult CAR T-cell Therapy Market Size and Forecast (2021-2032)
    • 7.3.3 France Aldult CAR T-cell Therapy Market Size and Forecast (2021-2032)
    • 7.3.4 United Kingdom Aldult CAR T-cell Therapy Market Size and Forecast (2021-2032)
    • 7.3.5 Russia Aldult CAR T-cell Therapy Market Size and Forecast (2021-2032)
    • 7.3.6 Italy Aldult CAR T-cell Therapy Market Size and Forecast (2021-2032)

8 Asia-Pacific

  • 8.1 Asia-Pacific Aldult CAR T-cell Therapy Consumption Value by Type (2021-2032)
  • 8.2 Asia-Pacific Aldult CAR T-cell Therapy Consumption Value by Application (2021-2032)
  • 8.3 Asia-Pacific Aldult CAR T-cell Therapy Market Size by Region
    • 8.3.1 Asia-Pacific Aldult CAR T-cell Therapy Consumption Value by Region (2021-2032)
    • 8.3.2 China Aldult CAR T-cell Therapy Market Size and Forecast (2021-2032)
    • 8.3.3 Japan Aldult CAR T-cell Therapy Market Size and Forecast (2021-2032)
    • 8.3.4 South Korea Aldult CAR T-cell Therapy Market Size and Forecast (2021-2032)
    • 8.3.5 India Aldult CAR T-cell Therapy Market Size and Forecast (2021-2032)
    • 8.3.6 Southeast Asia Aldult CAR T-cell Therapy Market Size and Forecast (2021-2032)
    • 8.3.7 Australia Aldult CAR T-cell Therapy Market Size and Forecast (2021-2032)

9 South America

  • 9.1 South America Aldult CAR T-cell Therapy Consumption Value by Type (2021-2032)
  • 9.2 South America Aldult CAR T-cell Therapy Consumption Value by Application (2021-2032)
  • 9.3 South America Aldult CAR T-cell Therapy Market Size by Country
    • 9.3.1 South America Aldult CAR T-cell Therapy Consumption Value by Country (2021-2032)
    • 9.3.2 Brazil Aldult CAR T-cell Therapy Market Size and Forecast (2021-2032)
    • 9.3.3 Argentina Aldult CAR T-cell Therapy Market Size and Forecast (2021-2032)

10 Middle East & Africa

  • 10.1 Middle East & Africa Aldult CAR T-cell Therapy Consumption Value by Type (2021-2032)
  • 10.2 Middle East & Africa Aldult CAR T-cell Therapy Consumption Value by Application (2021-2032)
  • 10.3 Middle East & Africa Aldult CAR T-cell Therapy Market Size by Country
    • 10.3.1 Middle East & Africa Aldult CAR T-cell Therapy Consumption Value by Country (2021-2032)
    • 10.3.2 Turkey Aldult CAR T-cell Therapy Market Size and Forecast (2021-2032)
    • 10.3.3 Saudi Arabia Aldult CAR T-cell Therapy Market Size and Forecast (2021-2032)
    • 10.3.4 UAE Aldult CAR T-cell Therapy Market Size and Forecast (2021-2032)

11 Market Dynamics

  • 11.1 Aldult CAR T-cell Therapy Market Drivers
  • 11.2 Aldult CAR T-cell Therapy Market Restraints
  • 11.3 Aldult CAR T-cell Therapy Trends Analysis
  • 11.4 Porters Five Forces Analysis
    • 11.4.1 Threat of New Entrants
    • 11.4.2 Bargaining Power of Suppliers
    • 11.4.3 Bargaining Power of Buyers
    • 11.4.4 Threat of Substitutes
    • 11.4.5 Competitive Rivalry

12 Industry Chain Analysis

  • 12.1 Aldult CAR T-cell Therapy Industry Chain
  • 12.2 Aldult CAR T-cell Therapy Upstream Analysis
  • 12.3 Aldult CAR T-cell Therapy Midstream Analysis
  • 12.4 Aldult CAR T-cell Therapy Downstream Analysis

13 Research Findings and Conclusion

    14 Appendix

    • 14.1 Methodology
    • 14.2 Research Process and Data Source

    According to our (Global Info Research) latest study, the global Aldult CAR T-cell Therapy market size was valued at US$ million in 2025 and is forecast to a readjusted size of US$ million by 2032 with a CAGR of %during review period.
    This report is a detailed and comprehensive analysis for global Aldult CAR T-cell Therapy market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
    Key Features:
    Global Aldult CAR T-cell Therapy market size and forecasts, in consumption value ($ Million), 2021-2032
    Global Aldult CAR T-cell Therapy market size and forecasts by region and country, in consumption value ($ Million), 2021-2032
    Global Aldult CAR T-cell Therapy market size and forecasts, by Type and by Application, in consumption value ($ Million), 2021-2032
    Global Aldult CAR T-cell Therapy market shares of main players, in revenue ($ Million), 2021-2026
    The Primary Objectives in This Report Are:
    To determine the size of the total market opportunity of global and key countries
    To assess the growth potential for Aldult CAR T-cell Therapy
    To forecast future growth in each product and end-use market
    To assess competitive factors affecting the marketplace
    This report profiles key players in the global Aldult CAR T-cell Therapy market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Bristol Myers Squibb，BMS, Johnson & Johnson, Gilead Sciences, Novartis, JW Therapeutics, Imunopharm Technology Co., Ltd., CARsgen Therapeutics, Cartesian Therapeutics, etc.
    This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
    Market segmentation
    Aldult CAR T-cell Therapy market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
    Market segment by Type
    CD19
    BCMA
    Others
    Market segment by Application
    Multiple Myeloma
    B-Cell Lymphoma (BCL)
    Acute Lymphoblastic Leukemia (ALL)
    Others
    Market segment by players, this report covers
    Bristol Myers Squibb，BMS
    Johnson & Johnson
    Gilead Sciences
    Novartis
    JW Therapeutics
    Imunopharm Technology Co., Ltd.
    CARsgen Therapeutics
    Cartesian Therapeutics
    Market segment by regions, regional analysis covers
    North America (United States, Canada and Mexico)
    Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
    Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
    South America (Brazil, Rest of South America)
    Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
    The content of the study subjects, includes a total of 13 chapters:
    Chapter 1, to describe Aldult CAR T-cell Therapy product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top players of Aldult CAR T-cell Therapy, with revenue, gross margin, and global market share of Aldult CAR T-cell Therapy from 2021 to 2026.
    Chapter 3, the Aldult CAR T-cell Therapy competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
    Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2021 to 2032.
    Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2021 to 2026.and Aldult CAR T-cell Therapy market forecast, by regions, by Type and by Application, with consumption value, from 2027 to 2032.
    Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
    Chapter 12, the key raw materials and key suppliers, and industry chain of Aldult CAR T-cell Therapy.
    Chapter 13, to describe Aldult CAR T-cell Therapy research findings and conclusion.

    Buy now